EQS-Adhoc: Change of President and CEO at Carl Zeiss Meditec AG
|
EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Personnel
Contact for investors and press Sebastian Frericks
End of Inside Information
07-May-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Carl Zeiss Meditec AG |
| Göschwitzer Str. 51-52 | |
| 07745 Jena, Germany | |
| Germany | |
| Phone: | +49 (0)3641 220-0 |
| Fax: | +49 (0)3641 220-112 |
| E-mail: | investors.meditec@zeiss.com |
| Internet: | www.zeiss.de/meditec-ag/ir |
| ISIN: | DE0005313704 |
| WKN: | 531370 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2132254 |
| End of Announcement | EQS News Service |
|
|
2132254 07-May-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 1.459,32 | 1.335,45 | 1.646,79 | 1.902,84 | 2.089,30 | 2.066,13 | 2.145,00 | |
| EBITDA1,2 | 313,03 | 237,98 | 435,20 | 466,65 | 422,19 | 327,22 | 333,00 | |
| EBITDA-Margin3 | 21,45 | 17,82 | 26,43 | 24,52 | 20,21 | 15,84 | 15,52 | |
| EBIT1,4 | 264,66 | 177,55 | 373,61 | 396,88 | 348,12 | 194,45 | 201,00 | |
| EBIT-Margin5 | 18,14 | 13,30 | 22,69 | 20,86 | 16,66 | 9,41 | 9,37 | |
| Net Profit (Loss)1 | 160,58 | 123,42 | 237,52 | 295,91 | 292,01 | 180,15 | 185,40 | |
| Net-Margin6 | 11,00 | 9,24 | 14,42 | 15,55 | 13,98 | 8,72 | 8,64 | |
| Cashflow1,7 | 219,63 | 178,53 | 362,66 | 188,20 | 250,86 | 247,32 | 255,00 | |
| Earnings per share8 | 1,79 | 1,37 | 2,64 | 3,29 | 3,25 | 2,01 | 2,08 | |
| Dividend per share8 | 0,65 | 0,50 | 0,90 | 1,10 | 1,10 | 0,60 | 0,60 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Carl Zeiss Meditec | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 531370 | DE0005313704 | AG | 3.885,30 Mio € | 22.03.2000 | Halten | 9F2HVHPW+8C |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 17,04 | 31,45 | 0,54 | 21,07 | 1,95 | 15,71 | 1,88 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,10 | 0,60 | 0,60 | 1,38% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.03.2025 | 12.02.2025 | 14.05.2025 | 07.08.2025 | 11.12.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -1,59% | -15,77% | -4,57% | -25,23% | +49,79% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
